GlassScriptPhysician profile
John G Bohlen
NPI 1689665242
$2,370.73
in general payments reported to CMS, 2019-2025
33 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $427 · 2021: $497 · 2022: $519 · 2023: $183 · 2024: $157 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $298.12 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $252.45 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $216.17 | 2019-2021 | |
| Amgen INC. | $213.16 | 2019-2023 | Evenity, Prolia |
| Astellas Pharma US INC | $161.83 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.77 | 2021-2025 | |
| Abbvie INC. | $141.97 | 2021-2023 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.83 | 2022-2023 | Jardiance |
| Lilly USA, LLC | $76.34 | 2019-2022 | |
| Eisai INC. | $71.16 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $68.61 | 2020-2022 | |
| Novo Nordisk INC | $58.46 | 2019-2021 | |
| Exact Sciences Corporation | $58.42 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.66 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $41.40 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.26 | 2023-2024 | Shingrix, Arexvy |
| Abbott Laboratories | $38.37 | 2022 | |
| Dexcom, INC. | $37.51 | 2024 | Dexcom G6 Transmitter |
| Sun Pharmaceutical Industries INC. | $36.81 | 2020 | |
| Daiichi Sankyo INC. | $31.31 | 2021 | |
| Supernus Pharmaceuticals, INC. | $28.11 | 2019 | |
| Allergan, INC. | $27.01 | 2019-2020 | |
| Lucid Diagnostics INC. | $17.81 | 2023 | |
| Avanir Pharmaceuticals, INC. | $17.56 | 2019 | |
| Boston Scientific Corporation | $17.41 | 2020 | |
| Idorsia Pharmaceuticals US INC | $17.34 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $15.27 | 2024 | Inspire |
| Almatica Pharma LLC | $14.94 | 2022 | |
| Mylan Specialty L.P. | $14.57 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.40 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $14.29 | 2021 | |
| Medtronic, INC. | $11.95 | 2022 | |
| Evoke Pharma, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bohlen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.